(EMR) Emerson Electric - Ratings and Ratios
Valves, Instruments, Actuators, Controllers, Tools
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.63% |
| Yield on Cost 5y | 3.09% |
| Yield CAGR 5y | 1.19% |
| Payout Consistency | 98.2% |
| Payout Ratio | 35.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 27.1% |
| Value at Risk 5%th | 39.3% |
| Relative Tail Risk | -11.95% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.03 |
| Alpha | -15.35 |
| CAGR/Max DD | 0.46 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.533 |
| Beta | 1.229 |
| Beta Downside | 1.355 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.62% |
| Mean DD | 7.83% |
| Median DD | 7.42% |
Description: EMR Emerson Electric September 26, 2025
Emerson Electric Co. (NYSE: EMR) is a diversified technology and software firm headquartered in St. Louis, Missouri, with operations spanning the Americas, Asia, the Middle East, Africa, and Europe.
The business is organized into six segments: Final Control; Measurement & Analytical; Discrete Automation; Safety & Productivity; Control Systems & Software; and Test & Measurement. Across these segments the company supplies a broad portfolio that includes control, isolation, shut-off, pressure-relief, and safety valves, as well as actuators and regulators for process and hybrid industries.
Its instrumentation line measures key physical properties of liquids and gases-pressure, temperature, level, flow, acoustics, corrosion, pH, conductivity, water quality, toxic gases, and flame detection-while its valve and pneumatic offerings cover solenoid and pneumatic valves, position indicators, cylinders, air-preparation equipment, and electric linear-motion solutions.
Emerson also delivers automation hardware such as programmable control systems, electrical distribution gear, and materials-joining technologies, complemented by a professional-tool segment that serves both contractors and homeowners with pipe-working, hydraulic, and electrical tools.
On the software side, the firm provides control-system architectures, safety-instrumented systems, SCADA platforms, digital-twin and asset-performance-management tools, and cybersecurity solutions. Its test-and-measurement business offers software-connected automated systems, while its asset-optimization suite leverages decades of modeling, simulation, and optimization to improve industrial performance.
Key recent metrics: FY 2023 revenue reached $20.5 billion, operating margin held near 14 percent, and free cash flow topped $2.1 billion; the dividend yield is roughly 2.5 percent with a five-year payout growth rate of about 6 percent. The Discrete Automation and Control Systems & Software segments have been the primary drivers of double-digit top-line growth, reflecting robust capital-expenditure cycles in oil-&-gas, chemicals, and the expanding renewable-energy infrastructure.
Sector-level trends that underpin Emerson’s outlook include accelerating industrial automation adoption, heightened focus on energy-transition assets that require advanced process control, and increasing regulatory pressure for safety-instrumented systems-factors that collectively boost demand for Emerson’s integrated hardware-software solutions.
For a deeper dive into Emerson’s valuation metrics and scenario analysis, the ValueRay platform offers a transparent, data-driven view worth checking out.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (2.29b TTM) > 0 and > 6% of Revenue (6% = 1.08b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -6.74% (prev 25.44%; Δ -32.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 3.10b > Net Income 2.29b (YES >=105%, WARN >=100%) |
| Net Debt (12.21b) to EBITDA (4.95b) ratio: 2.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (565.5m) change vs 12m ago -1.55% (target <= -2.0% for YES) |
| Gross Margin 52.84% (prev 50.79%; Δ 2.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.79% (prev 39.53%; Δ 2.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.15 (EBITDA TTM 4.95b / Interest Expense TTM 356.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.42
| (A) -0.03 = (Total Current Assets 8.58b - Total Current Liabilities 9.80b) / Total Assets 41.96b |
| (B) 0.97 = Retained Earnings (Balance) 40.60b / Total Assets 41.96b |
| warn (B) unusual magnitude: 0.97 — check mapping/units |
| (C) 0.08 = EBIT TTM 3.26b / Avg Total Assets 43.10b |
| (D) 1.86 = Book Value of Equity 40.26b / Total Liabilities 21.67b |
| Total Rating: 5.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.41
| 1. Piotroski 7.0pt |
| 2. FCF Yield 3.16% |
| 3. FCF Margin 14.80% |
| 4. Debt/Equity 0.68 |
| 5. Debt/Ebitda 2.47 |
| 6. ROIC - WACC (= -0.87)% |
| 7. RoE 11.48% |
| 8. Rev. Trend 67.83% |
| 9. EPS Trend 35.94% |
What is the price of EMR shares?
Over the past week, the price has changed by +6.24%, over one month by -1.82%, over three months by -1.08% and over the past year by +0.82%.
Is EMR a buy, sell or hold?
- Strong Buy: 19
- Buy: 3
- Hold: 6
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the EMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 150.5 | 14.5% |
| Analysts Target Price | 150.5 | 14.5% |
| ValueRay Target Price | 144.9 | 10.2% |
EMR Fundamental Data Overview November 25, 2025
P/E Trailing = 31.8164
P/E Forward = 19.8413
P/S = 4.0055
P/B = 3.5516
P/EG = 1.3672
Beta = 1.25
Revenue TTM = 18.02b USD
EBIT TTM = 3.26b USD
EBITDA TTM = 4.95b USD
Long Term Debt = 8.32b USD (from longTermDebt, last quarter)
Short Term Debt = 4.93b USD (from shortTermDebt, last quarter)
Debt = 13.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.21b USD (from netDebt column, last quarter)
Enterprise Value = 84.38b USD (72.16b + Debt 13.76b - CCE 1.54b)
Interest Coverage Ratio = 9.15 (Ebit TTM 3.26b / Interest Expense TTM 356.0m)
FCF Yield = 3.16% (FCF TTM 2.67b / Enterprise Value 84.38b)
FCF Margin = 14.80% (FCF TTM 2.67b / Revenue TTM 18.02b)
Net Margin = 12.73% (Net Income TTM 2.29b / Revenue TTM 18.02b)
Gross Margin = 52.84% ((Revenue TTM 18.02b - Cost of Revenue TTM 8.50b) / Revenue TTM)
Gross Margin QoQ = 51.91% (prev 52.56%)
Tobins Q-Ratio = 2.01 (Enterprise Value 84.38b / Total Assets 41.96b)
Interest Expense / Debt = 0.67% (Interest Expense 92.0m / Debt 13.76b)
Taxrate = 20.10% (160.0m / 796.0m)
NOPAT = 2.60b (EBIT 3.26b * (1 - 20.10%))
Current Ratio = 0.88 (Total Current Assets 8.58b / Total Current Liabilities 9.80b)
Debt / Equity = 0.68 (Debt 13.76b / totalStockholderEquity, last quarter 20.28b)
Debt / EBITDA = 2.47 (Net Debt 12.21b / EBITDA 4.95b)
Debt / FCF = 4.58 (Net Debt 12.21b / FCF TTM 2.67b)
Total Stockholder Equity = 19.97b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.46% (Net Income 2.29b / Total Assets 41.96b)
RoE = 11.48% (Net Income TTM 2.29b / Total Stockholder Equity 19.97b)
RoCE = 11.52% (EBIT 3.26b / Capital Employed (Equity 19.97b + L.T.Debt 8.32b))
RoIC = 8.07% (NOPAT 2.60b / Invested Capital 32.27b)
WACC = 8.94% (E(72.16b)/V(85.92b) * Re(10.54%) + D(13.76b)/V(85.92b) * Rd(0.67%) * (1-Tc(0.20)))
Discount Rate = 10.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.68%
[DCF Debug] Terminal Value 67.87% ; FCFE base≈2.77b ; Y1≈2.52b ; Y5≈2.22b
Fair Price DCF = 48.20 (DCF Value 27.08b / Shares Outstanding 561.8m; 5y FCF grow -11.07% → 3.0% )
EPS Correlation: 35.94 | EPS CAGR: 12.26% | SUE: 0.0 | # QB: 0
Revenue Correlation: 67.83 | Revenue CAGR: 12.17% | SUE: -0.47 | # QB: 0
Additional Sources for EMR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle